Astrocytic NDRG2-PPM1A interaction exacerbates blood-brain barrier disruption after subarachnoid hemorrhage
- Sci Adv. 2022 Sep 30;8(39):eabq2423. doi: 10.1126/sciadv.abq2423.
- 1. Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, International Cooperation Platform for Encephalopathy of Shaanxi Province, Xi'an 710038, China.
- 2. Department of Medical Genetics and Development Biology, Fourth Military Medical University, Xi'an 710032, China.
- 3. Department of Biological Sciences, Xinyang Normal University, Xinyang 464000, China.
- 4. Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
- 5. Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an 710032, China.
Blood-brain barrier (BBB) injury critically exacerbates the poor prognosis of patients with subarachnoid hemorrhage (SAH). The massively increased Matrix Metalloproteinases 9 (MMP-9) plays a deleterious role in BBB. However, the main source and mechanism of MMP-9 production after SAH remain unclear. We reported that the increased MMP-9 was mainly derived from reactive astrocytes after SAH. Ndrg2 knockout in astrocytes inhibited MMP-9 expression after SAH and attenuated BBB damage. Astrocytic Ndrg2 knockout decreased the phosphorylation of SMAD2/3 and the transcription of MMP-9. Notably, cytoplasmic NDRG2 bound to the protein Phosphatase PPM1A and restricted the dephosphorylation of SMAD2/3. Accordingly, TAT-QFNP12, a novel engineered peptide that could block the NDRG2-PPM1A binding and reduce SMAD2/3 dephosphorylation, decreased astrocytic MMP-9 production and BBB disruption after SAH. In conclusion, this study identified NDRG2-PPM1A signaling in reactive astrocytes as a key switch for MMP-9 production and provided a novel therapeutic avenue for BBB protection after SAH.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Neurological Disease
-
Research Areas: Neurological Disease
-
Cat. No.Product NameCategory/Application